GLP-1s like Ozempic are among the most important drug breakthroughs ever
Their far-reaching potential could transform how chronic diseases are managed
IN THE HISTORY of medicine, a few drugs tower above all others. Humira for rheumatoid arthritis; Prozac for depression; statins to prevent heart disease and strokes. All have helped patients far beyond doctors’ initial expectations and continue to benefit millions of people every day. A new class of drugs is set to join their ranks and has the potential to eclipse them all—GLP-1 receptor agonists.
This article appeared in the Briefing section of the print edition under the headline “One jab to treat them all”
From the October 26th 2024 edition
Discover stories from this section and more in the list of contents
Explore the editionMore from Briefing
The right in Congress and the courts will reshape Donald Trump’s agenda
As dominant as the new president is, there is still life in Washington’s institutions
How far will Donald Trump go to get rid of illegal immigrants?
It is his signature policy, but the obstacles are daunting
Young customers in developing countries propel a boom in plastic surgery
Falling costs and converging beauty standards spur new habits
The Assad regime’s fall voids many of the Middle East’s old certainties
What if Syria abandoned its hostility to the West and stopped menacing Israel?
Syria has exchanged a vile dictator for an uncertain future
It is not clear how stable or how benign the new regime will be
Gambling is growing like gangbusters in America
Technology and legal changes are spurring a betting bonanza